| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Claire Harrison | |
| Samah Alimam | |||
| P2860 | cites work | MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives | Q26775996 |
| Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management | Q26851894 | ||
| The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia | Q27853375 | ||
| Efficacy and safety of low-dose aspirin in polycythemia vera | Q28166691 | ||
| Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study | Q28211348 | ||
| Management of polycythaemia vera: a critical review of current data | Q31009757 | ||
| Fear of needles and vasovagal reactions among phlebotomy patients | Q33153547 | ||
| Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis | Q33405766 | ||
| Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis | Q33411211 | ||
| A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea | Q33411637 | ||
| Safety evaluation of ruxolitinib for treating myelofibrosis | Q33415731 | ||
| Ruxolitinib versus standard therapy for the treatment of polycythemia vera. | Q33420037 | ||
| Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study | Q33437373 | ||
| Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study | Q34037065 | ||
| Polycythemia vera: myths, mechanisms, and management | Q34977300 | ||
| The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera | Q35433005 | ||
| The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis | Q36091279 | ||
| Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. | Q36311347 | ||
| Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET) | Q36563878 | ||
| Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera | Q36938773 | ||
| Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms | Q36946576 | ||
| Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a | Q37083947 | ||
| Evidence and expertise in the management of polycythemia vera and essential thrombocythemia | Q37205823 | ||
| Kinase drug discovery approaches in chronic myeloproliferative disorders | Q37472874 | ||
| Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies | Q37552023 | ||
| The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). | Q37561170 | ||
| Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms | Q38097513 | ||
| Emerging drugs for polycythemia vera | Q38130749 | ||
| Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea | Q38187684 | ||
| Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options | Q38255717 | ||
| Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. | Q38393343 | ||
| Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. | Q40129814 | ||
| Vascular and neoplastic risk in a large cohort of patients with polycythemia vera | Q40445951 | ||
| The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. | Q40463923 | ||
| From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera | Q41345864 | ||
| Corrigendum to "Combination therapy with interferon and JAK1-2 inhibitor is feasible. Proof of concept with rapid reduction in JAK2V617F-allele burden in Polycythemia Vera" [Leuk. Res. Rep. 3 (2) (2014) 73-75]. | Q42426410 | ||
| A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process | Q43237567 | ||
| Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. | Q44174767 | ||
| Treatment target in polycythemia vera | Q44789627 | ||
| Cardiovascular events and intensity of treatment in polycythemia vera | Q44793541 | ||
| A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. | Q45994535 | ||
| Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis | Q46636672 | ||
| How I treat polycythemia vera. | Q48263925 | ||
| Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. | Q50671166 | ||
| Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. | Q50761284 | ||
| A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. | Q53312448 | ||
| Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. | Q54341051 | ||
| Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera | Q58416020 | ||
| Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera | Q61146044 | ||
| Recombinant interferon-alpha for treatment of polycythaemia vera | Q69921729 | ||
| Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia | Q71777805 | ||
| Treatment of polycythemia vera with busulfan (myleran) | Q78426990 | ||
| Epidemiology of myeloproliferative neoplasms in the United States | Q86953148 | ||
| Ruxolitinib versus standard therapy for the treatment of polycythemia vera | Q87165862 | ||
| P433 | issue | 4 | |
| P921 | main subject | ruxolitinib | Q7383611 |
| P304 | page(s) | 139-151 | |
| P577 | publication date | 2017-04-01 | |
| P1433 | published in | Therapeutic advances in hematology | Q26842172 |
| P1476 | title | Experience with ruxolitinib in the treatment of polycythaemia vera | |
| P478 | volume | 8 |
Search more.